secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001193125-23-002979
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea BioTherapeutics COO Leslie Sloan departs Jan 5, 2023; receives severance package
--------------------------------------------------------------------------------

- COO Leslie Sloan departed Jan 5, 2023; departure not tied to legal or compliance matters.
- Severance includes $435,000 salary continuation (12 months), $174,000 lump-sum bonus, and 12 months COBRA coverage.
- Unvested stock options accelerate vesting for an additional 12 months beyond separation date.
- No successor COO has been announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523002979/0001193125-23-002979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523002979/d380211d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-002979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer